萬隆控股集團(00030.HK):延長認購事項最後期限至2020年2月28日
格隆匯12月31日丨萬隆控股集團(00030.HK)公佈,公司已於10月14日與雲南白藥集團訂立認購協議,雲南白藥集團擬認購公司已發行的7.3億港元可換股債券,認購價等於可換股債券的本金總額。由於公司需要額外時間編制及落實通函,公司現時預計通函將進一步延遲至2020年1月31日或之前寄發。
根據認購協議,達成或豁免條件的最後期限原定於2019年12月31日。為讓各方有更多時間達成條件,於2019年12月31日,公司與雲南白藥集團訂立補充協議,將最後期限延長至2020年2月28日。除延長最後期限外,認購協議的所有其他條款及條件均維持不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.